FOXD2 and neoplasm: Overexpression of FOXD2-AS1 can accelerate tumor development and predict poor prognosis in GC patients by EZH2 binding to the region of EphB3 promoter and inducing H3K27me3 modification, or LSD1 combining with the region of EphB3 promoter and inducing demethylation of H3K4, ultimately epigenetically silencing of EphB3 (121).